Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nelarabine

Next Previous
Drug Profile

Nelarabine

Alternative Names: 506U; 506U78; Arranon; Atriance; C 506; Compound 506; GW 506U; GW 506U78; Nelzarabine

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer National Cancer Institute (USA); Novartis
  • Class Antineoplastics; Arabinonucleosides; Small molecules
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 14 Jul 2017 No recent reports on development identified - Phase-I/II for Acute lymphoblastic leukaemia and T-cell lymphoma (Combination therapy, Second-line therapy or greater) in Australia, Canada, Austria, France, Italy, Netherlands, United Kingdom and USA (IV)
  • 04 Jun 2015 Nelarabine is still in phase III development for Acute lymphoblastic leukaemia (Combination therapy, First-line therapy) and T-cell lymphoma (Combination therapy, First-line therapy) in Australia, Canada, New Zealand, Switzerland and USA
  • 04 Jun 2015 Nelarabine is still in phase I/II development for Acute lymphoblastic leukaemia (Combination therapy, Second-line therapy or greater) and T-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA, Canada, Australia, Austria, France, Italy and Netherlands
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top